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MinireviewParkin: A Multipurpose
Neuroprotective Agent?
targets with ubiquitin is responsible for dopaminergic
neuron death in this disorder.
While AR-JP patients display many of the clinical fea-
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parkin may promote the formation of Lewy body inclu-2 Department of Genome Sciences
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mediated neurodegeneration may proceed through aSeattle, Washington 98195
mechanism that is distinct from that of idiopathic PD. In
vitro experiments premised upon the former hypothesis
have shown that parkin can induce the ubiquitination of
An autosomal recessive juvenile-onset form of Parkin- -synuclein, a major component of Lewy body inclu-
son’s disease (AR-JP) is caused by loss-of-function sions and one of the factors implicated in PD from link-
mutations of the parkin gene, which encodes a ubiqui- age studies (Shimura et al., 2001). However, parkin is
tin-protein ligase. Three recent reports demonstrate only capable of binding to and catalyzing ubiquitination
that parkin can protect neurons from diverse cellular of a rare glycosylated form of -synuclein (-Sp22). Nev-
insults, including -synuclein toxicity, proteasomal dys- ertheless, this minor form of -synuclein appears to ac-
function, Pael-R accumulation, and kainate-induced ex- cumulate in the brains of AR-JP individuals, thus sup-
citotoxicity. These findings suggest a central role for porting its potential involvement in this disorder.
parkin in maintaining dopaminergic neuronal integrity Additional work has shown that parkin can bind to and
and strengthen the link between AR-JP and the more ubiquitinate the -synuclein binding protein synphilin-1
common sporadic form of Parkinson’s disease. (Chung et al., 2001). Furthermore, parkin protein appears
to localize to Lewy body inclusions in vivo (Shimura et
al., 1999; Choi et al., 2000, 2001; Schlossmacher et al.,
2002), and the formation of Lewy body-like inclusions inParkinson’s Disease (PD) is a common neurodegenera-
cultured cells is dependent on -synuclein, synphilin-1,tive disorder characterized by the loss of dopaminergic
and parkin expression (Chung et al., 2001). Together,neurons in the substantia nigra pars compacta and the
these results suggest that parkin promotes the forma-accumulation of proteinacous intraneuronal inclusions
tion of Lewy body inclusions and that Lewy body forma-known as Lewy bodies. While the molecular mecha-
tion may represent a mechanism to detoxify proteinsnisms responsible for neurodegeneration in PD remain
such as -synuclein.poorly understood, previous work implicates aberrant
Open-ended screening approaches to identify parkinproteolytic degradation and oxidative damage arising
binding components using the yeast two-hybrid systemfrom mitochondrial dysfunction or byproducts of dopa-
have also led to the recovery of parkin substrates (Zhangmine metabolism (Betarbet et al., 2002). Although most
et al., 2000; Imai et al., 2001). Among the polypeptidescases of PD do not have an obvious familial component,
identified in this work is the putative G protein-coupledlinkage studies have currently identified ten distinct loci
receptor Pael-R. Overexpression of Pael-R in culturedresponsible for rare Mendelian forms of this disorder
cells induces the expression of parkin and the ER chap-(Dawson and Dawson, 2003). The recent cloning and
erone BiP (GRP78) and results in increased cell death.
subsequent analysis of several of these genes has be-
A substantial fraction of the overexpressed Pael-R is
gun to reveal mechanistic insight into the pathogenesis
ubiquitinated and accumulates in an insoluble form, sug-
of this disorder. gesting that cell death results from unfolded protein
One of the genes identified from linkage studies of an stress. Co-overexpression of parkin leads to increased
early-onset form of PD known as autosomal recessive ubiquitination and degradation of Pael-R and mitigates
juvenile parkinsonism (AR-JP) is parkin (Kitada et al., Pael-R toxicity, suggesting that Pael-R may be an in
1998). The parkin gene encodes a polypeptide with a vivo target of parkin and that accumulation of Pael-R is
ubiquitin-like domain, a pair of RING finger motifs, and responsible for neuron death in AR-JP. Like glycosy-
an in-between RING finger (IBR) domain. Like many lated -synuclein, Pael-R protein also appears to accu-
other proteins with RING domains (Jackson et al., 2000), mulate in the brains of parkin individuals, providing fur-
parkin appears to function as an E3 ubiquitin protein ther support for this model.
ligase (Shimura et al., 2000; Zhang et al., 2000). E3 ubi- While the identification of glycosylated -synuclein,
quitin protein ligases act in concert with ubiquitin-acti- synphilin-1, Pael-R, and other parkin substrates provide
vating (E1) and ubiquitin-conjugating (E2) enzymes to suggestive clues to the mechanism of neuron loss in
confer substrate specificity in the ubiquitination path- AR-JP, previous work has failed to provide definitive
way. The finding that AR-JP results from loss of parkin evidence establishing a causative link between these
function suggests that failure to label specific cellular factors and dopaminergic neuron loss. Furthermore,
given that the parkin substrates thus far identified in-
clude both Lewy body components and factors that*Correspondence: mel_feany@hms.harvard.edu (M.B.F.), pallanck@
gs.washington.edu (L.J.P.) appear unrelated to Lewy body metabolism, the ques-
Neuron
14
tion of whether neurodegeneration proceeds through cultured neurons or brain sections from flies expressing
Pael-R or -synuclein alone, or in combination with hu-altered Lewy body metabolism or through an indepen-
dent pathway remains unresolved. Finally, most of the man parkin. Results from these studies revealed a re-
duction in the abundance of Pael-R in many (but not all)previously identified parkin binding components appear
to be substrates of parkin rather than parkin cofactors, neurons coexpressing parkin and Pael-R after 6 days in
culture with respect to age-matched control neuronsand thus, little is currently known of the pathways in
which parkin normally acts. Three recently published expressing only Pael-R, or neurons coexpressing Pael-R
and parkin at earlier time points. Identical results werepapers have begun to address these issues by demon-
strating a role for parkin in protecting neurons from observed in dopaminergic neurons, suggesting that par-
kin attenuates Pael-R toxicity by mediating the degrada-diverse insults: -synuclein toxicity, proteasomal inhibi-
tion, Pael-R accumulation, and kainate-induced excito- tion of this protein. The finding that parkin and Pael-R
largely colocalize suggests that parkin is directly in-toxicity.
To investigate the toxicity of Pael-R to dopaminergic volved in Pael-R degradation. By contrast, the overall
abundance of -synuclein appeared to be unaffectedneurons and the possible role of parkin in mediating
Pael-R toxicity, Yang et al. (2003) used a transgenic by coexpression of parkin. However, closer inspection
of brain sections from flies coexpressing parkin andapproach in Drosophila to express human Pael-R under
conditions of altered parkin activity. Results of this anal- -synuclein revealed a sharp reduction in the abun-
dance of -synuclein-positive grain-like structures andysis revealed that expression of human Pael-R at similar
levels in all neurons of the Drosophila brain results in ubiqiutin-positive Lewy body-like neurites that are ob-
served in flies expressing -synuclein alone. This obser-age-dependent degeneration of dopaminergic neurons
without detectably altering other neuronal cell types. vation suggests that parkin acts specifically on aberrant
-synuclein deposits.Pael-R-mediated dopaminergic neuron loss was attenu-
ated by coexpression of human parkin and exacerbated These studies are important because they provide the
first evidence that Pael-R is selectively toxic to dopamin-by inhibiting the activity of endogeneous fly parkin using
RNA interference (RNAi). Importantly, RNAi-mediated ergic neurons and that this toxicity, as well as -synu-
clein-mediated toxicity, is influenced by parkin. The find-partial inactivation of Drosophila parkin was found to
have no effect on dopaminergic neuron survival in the ing that parkin is able to mitigate -synuclein toxicity
is of particular significance because this observationabsence of Pael-R, suggesting that the cell loss medi-
ated by RNAi results from enhanced Pael-R toxicity. potentially links parkin to the more common form of
idiopathic PD, in which -synuclein-containing LewyDo these results invalidate models implicating parkin
in Lewy body metabolism? Recent in vitro studies by body inclusions are a common characteristic. However,
like many important studies, this work also raises a num-Petrucelli et al., as well as further studies in Drosophila
by Yang et al., suggest not. Using a mouse primary ber of new questions. Perhaps the most surprising result
reported by Yang et al. is the finding that parkin overex-midbrain cell culture system, Petrucelli et al. showed
that neuronal cell death could be induced by the addition pression suppresses the formation of Lewy body-like
aggregates. This result seems contrary to findings in AR-of proteasome inhibitors or by transducing cells with
an -synuclein derivative bearing one of the mutational JP individuals, where loss of parkin function is generally
associated with an absence of Lewy body pathology.changes responsible for familial PD. Moreover, the cell
death induced by these factors was restricted to cate- Further, this result suggests that Lewy body inclusions
are toxic, which again is difficult to reconcile with thecholaminergic neurons, suggesting that these cells are
particularly sensitive to proteasomal dysfunction and absence of these inclusions in most AR-JP individuals.
How might we account for these apparent contradic--synuclein toxicity. Increased expression of wild-type
human parkin in these cells, but not a parkin derivative tions? One possibility is that parkin is involved in both
the formation and breakdown of Lewy body inclusions.bearing an inactivating mutation, was found to rescue
the toxicity of proteasomal inhibition and -synuclein Perhaps low levels of parkin activity are sufficient to
support the formation of Lewy body inclusions, whereasexpression. Complementary results were obtained by
Yang et al. in Drosophila, by showing that the dopamin- higher levels of parkin activity simply bypass Lewy body
inclusion formation and instead direct the rapid destruc-ergic neuronal death that results from ectopic expres-
sion of human -synuclein protein (Feany and Bender, tion of aberrant -synuclein species. The ability of over-
expressed parkin to protect cultured primary mesence-2000) could be mitigated by co-overexpression of hu-
man parkin. The specificity of this interaction was dem- phalic neurons from -synuclein toxicity in the absence
of visible aggregate formation supports such a pathwayonstrated by showing that co-overexpression of the
green fluorescent protein had no effect on -synuclein- (Petrucelli et al., 2002). Alternatively, parkin may only
participate in the formation of Lewy body inclusions,mediated dopaminergic neuron death. Although use of
a human parkin protein bearing one of the inactivating and overexpression of human parkin in Drosophila may
activate other stress pathways that direct degradationmutations responsible for AR-JP would have been a
more convincing control for the effect of parkin overex- or disassembly of Lewy body inclusions. Also, the con-
comitant loss of Lewy body-like inclusions and suppres-pression in this in vivo study, these results, together
with the work of Petrucelli et al., support the model that sion of cellular toxicity in flies coexpressing parkin and
-synuclein are correlative and do not definitively ad-dopaminergic neuron loss in AR-JP results at least in
part from the ensuing toxicity of -synuclein. dress the nature of the toxic entity driving loss of dopa-
minergic neurons.To investigate the mechanisms by which parkin medi-
ates attenuation of Pael-R and -synuclein toxicity, Another question arising from the work of Yang et al.
concerns the mechanism by which aberrant -synucleinYang et al. performed immunocytochemical studies on
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is recognized and degraded by parkin. In particular, it experimental conditions used, complicating the inter-
pretation of these experiments.would be interesting to know if glycosylated -syn-
uclein is formed in Drosophila and degraded upon co- These experiments provide evidence that parkin
works as part of a complex similar to other E3 ligases,overexpression of parkin, or whether parkin targets an-
other -synuclein species. It will also be important to and suggest cyclin E as a novel parkin substrate. These
intriguing results leave a number of questions to beelucidate the pathway through which -synuclein and
Pael-R confer specific toxicity to dopaminergic neurons. addressed in future work. The in vivo role of the ob-
served biochemical interactions needs to be defined.Although previous work suggests that Pael-R acts by
inducing the unfolded protein response, it remains pos- Are hSel-10 and Cul1 critical mediators of parkin func-
tion in vivo? Are there other important substrates ofsible that toxicity arises from Pael-R-mediated induction
of a G protein-coupled pathway. The finding that Pael-R the complex besides cyclin E? It would be particularly
important to determine if cyclin E expression is sufficientexpression in the thorax results in an easily identified
phenotype that can be suppressed by co-overexpres- to sensitize neurons to kainate toxicity, or if other parkin
substrates also play a critical role (Figure 1).sion of parkin potentially provides a useful means to
conduct screens for modifiers, which should be informa- The basis of anatomic specificity in AR-JP also re-
mains unclear from this work. Elevation of cyclin E andtive about the mechanism of Pael-R toxicity. Finally, the
variability in Pael-R levels observed in cultured neurons related cell cycle markers is widespread in ischemic and
toxic models of neuronal injury in vivo (Copani et al.,coexpressing parkin warrants further explanation. Yang
et al. suggest that this finding might be explained by 2001), as is parkin expression. Thus, the specificity of
AR-JP for dopaminergic neurons remains enigmatic.variable expression of parkin-interacting proteins. If so,
this finding might partially explain the tissue specificity The possible connection with cell cycle activation is
intriguing and it will be of interest to determine if theof AR-JP, and thus the identification of these interacting
proteins is of utmost importance. elevation of cyclin E noted with decreased parkin ex-
pression is part of a concerted cell cycle activation pro-Staropoli et al. (2003) took a biochemical approach
to define such parkin-interacting proteins. Since a num- gram, or is instead part of an apoptotic cell death path-
way. In this regard, it is surprising that the authors seeber of RING domain-containing proteins function as part
of defined multiprotein complexes known as SCF (Skp1/ an increase in cyclin E levels in brains from patients with
sporadic Parkinson’s disease, but not in Alzheimer’scullin/F-box) complexes (reviewed in Jackson et al.,
2000), the authors determined if parkin could interact disease, because accumulation of cell cycle proteins is
a prominent feature of postmortem brain tissue fromwith known components of other E3 ligase complexes.
They found that parkin specifically interacted with hSel- patients with Alzheimer’s disease, but not from patients
with Parkinson’s disease (Husseman et al., 2000).10 (an F-box/WD protein also known as hCdc4, Archipel-
ago, and Fbw7) and Cullin-1 (Cul1), but not with other In concert, these three recent papers expand the po-
tential role of parkin to guard against Pael-R andF-box/WD proteins. The authors further demonstrated
that hSel-10 was associated with parkin in brain homog- -synuclein toxicity, proteasome dysfunction, and exci-
totoxic cell death. Intriguingly, parkin and each of theseenates and used the E2 UbcH7 to potentiate parkin
ubiquitin ligase activity. Cyclin E is a known substrate diverse insults have previously been implicated in the
pathogenesis of dopaminergic neuronal death in Parkin-of the SCFhSel-10 complex, and cyclin E was also recruited
to the parkin-Cul1 complex and ubiquitinated. Inhibition son’s disease. In addition, the current studies identify
a novel parkin substrate, cyclin E. Key areas for futureof parkin using RNAi increased levels of cyclin E, consis-
tent with a role for parkin in cyclin E degradation. work include demonstration that emerging parkin sub-
strates like cyclin E indeed play a critical role in dopamin-The identification of cyclin E as a parkin substrate
is intriguing because cyclin E, with its partner cyclin- ergic neurodegeneration in vivo. Defining a role for en-
dogenous parkin, as opposed to overexpressed parkin,dependent kinase 2, is a key regulator of the G1/S transi-
tion during the cell cycle. Inappropriate activity of cell in protecting dopaminergic neurons from -synuclein
toxicity will also be important. The mechanisms by whichcycle-related kinases, perhaps through activation of the
cell cycle, has been suggested as an important mediator parkin protects from diverse toxic insults remains to
be determined, but two recent papers suggest a finalof death in postmitotic neurons exposed to excitotoxins
like kainate (Copani et al., 2001). Thus, Staropoli et al. common pathway of parkin toxicity in vivo involving
mitochondrial swelling, cytochrome c release, and apo-assayed the ability of parkin overexpression to protect
from kainate-induced cell death. Overexpression of par- ptotic cell death (Figure 1). In the first study, overexpres-
sion of parkin protected PC12 cells from cell death medi-kin rescued cultured cerebellar granular cells and mid-
brain dopaminergic neurons from kainate-induced cell ated by ceramide (Darios et al., 2003). In these PC12
cells, parkin acted by delaying mitochondrial swellingdeath. Parkin-mediated protection correlated with de-
creased cyclin E accumulation. Conversely, reducing and cytochrome c release. Parkin copurified with mito-
chondria in PC12 cells and was localized on the outerparkin levels with RNAi sensitized cerebellar granular
cells and midbrain dopaminergic neurons to kainate tox- mitochondrial membrane. Similarly, Drosophila com-
pletely lacking parkin exhibited adult-onset muscle de-icity. Interestingly, reducing parkin levels had no influ-
ence on MPP toxicity, suggesting that pathways medi- generation characterized by mitochondrial swelling and
subsequent apoptosis of myocytes (Greene et al., 2003).ating dopaminergic toxicity of the two compounds were
distinct. Cyclin E levels were also not elevated in cul- Male parkin mutant flies were also sterile. Analysis of
the male germline revealed pronounced pathology oftured neurons treated with MPP, further suggesting
that pathways of toxicity were distinct. However, MPP the mitochondrial derivatives that form the sperm tail,
suggesting that mitochondrial dysfunction is a commonhad substantially less toxicity than kainate under the
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Figure 1. A Model Summarizing the Path-
ways Regulated by Parkin and the Effects of
Loss of Parkin Function
Parkin can mediate ubiquitination of unfolded
PaelR, glycosylated -synuclein (-sp22),
cyclin E, and other known and possibly un-
known substrates. Although parkin is capable
of assembling with an E2 enzyme, hSel10,
Cul1, and possibly other factors, it is unclear
whether ubiquitination of all parkin substrates
requires assembly with all of these factors.
Following ubiquitination, the parkin sub-
strates are directed for proteolytic degrada-
tion by the proteasome. In AR-JP patients,
lack of parkin function leads to the accumula-
tion of PaelR, -sp22, cyclin E, and possibly
other factors. The accumulation of these fac-
tors may trigger mitochondrial swelling, pos-
sibly leading to oxidative stress, cytochrome
C release, and ultimately apoptotic cell death.
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